D. Boral Capital Reaffirms Buy Rating for Compass Therapeutics (NASDAQ:CMPX)
Compass Therapeutics (NASDAQ:CMPX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $32.00 price objective on the stock. Several other equities research analysts also recently issued reports on the company. Piper Sandler began coverage […]
Compass Therapeutics (NASDAQ:CMPX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $32.00 price objective on the stock. Several other equities research analysts also recently issued reports on the company. Piper Sandler began coverage […]
